Results 181 to 190 of about 214,341 (267)
In a multi‐center Canadian cohort of 577 patients with advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer treated with first/second‐generation TKIs, Asian ancestry and female sex predicted longer survival, while the L858R mutation predicted shorter survival.
Heather Halperin +10 more
wiley +1 more source
Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review. [PDF]
Goto K +6 more
europepmc +1 more source
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern +11 more
wiley +1 more source
Understanding immune checkpoint inhibitor efficacy through spatial decoding of the lung cancer tumor immune microenvironment. [PDF]
Zou T, Minna JD.
europepmc +1 more source
Oncology Inpatient Resuscitation Planning and Long‐Term “Rapid Response Call” Outcomes
Optimal end‐of‐life care involves a patient‐centered approach. The dual audits presented in this study show that a proportion of oncology patients receiving palliative‐intent cancer treatment continue to be managed in hospital without a resuscitation plan and may undergo care escalation to a “rapid response” intervention despite poor prognosis ...
Dhanashree Tikhe +3 more
wiley +1 more source
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care. [PDF]
Nath A +21 more
europepmc +1 more source
ABSTRACT Background/Objectives Epidermal growth factor receptor inhibitors (EGFRi) commonly cause papulopustular exanthemas that may compromise the success of cancer therapy. While tetracyclines are first‐line treatment, data on alternative systemic agents for refractory cases remain limited.
Ishana Dixit +2 more
wiley +1 more source
Practice-Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025. [PDF]
Zhou Z, Gao W, Li MSC, Zhou Q.
europepmc +1 more source
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, Elyce Cardonick
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source

